Date: 2013-10-07
Type of information: Nomination
Compound:
Company: Melinta Therapeutics (USA - CT)
Therapeutic area: Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On October 7, 2013, Melinta Therapeutics announced the appointment of Lyn Baranowski as senior vice president, corporate development and strategy. In this role, Baranowski is responsible for structuring, negotiating and executing successful strategic alliances, licensing agreements, M&A transactions, and financial investments, as well as providing business development, management and strategic leadership to the organization. She is a member of the executive leadership team. Previously, Baranowski was vice president of commercial development at Pearl Therapeutics and was instrumental in driving the company’s corporate development activities including its recent sale to AstraZeneca for $1.15 billion. Before her role at Pearl Therapeutics, Baranowski served as vice president of Vatera Healthcare Partners, a healthcare-focused venture capital firm based in New York where she was responsible for lead identification, evaluation, and negotiation as well as working with management teams of portfolio companies to develop and implement business plans.
- Melinta Therapeutics, formerly Rib-X Pharmaceuticals, has recenly launched of a new corporate identity, an important milestone in the company’s evolution. Melinta’s new strategic direction leverages the Nobel Prize-winning science developed by Rib-X’s founders. To accelerate the product portfolio, the company will be led by a new management team with experience launching and building pharmaceutical brands. The driving force behind this new strategic direction is Melinta’s new lead investor, the specialized venture capital firmVatera Healthcare Partners.
- Melinta’s lead antibiotic candidate, delafloxacin, a novel fluoroquinolone, is being developed to treat acute bacterial skin and skin structure infections (ABSSSI) and hospital-acquired bacterial pneumonia. Delafloxacin is currently in Phase 3 development in oral and IV formulations for ABSSSI, a major reason for hospitalizations in the U.S., often caused by methicillin-resistant Staphylococcus aureus (MRSA). Delafloxacin is designated as a Qualified Infectious Disease Product (QIDP) by the FDA in ABSSSI as well as hospital- and community-acquired bacterial pneumonia.
- Melinta also has several earlier-stage antibiotic development programs that are derived from the company’s proprietary knowledge of the structure and function of the bacterial ribosome. Among these development programs is RX-04, in which Melinta synthesized a new class of antibiotics, the pyrrolocytosines, which have demonstrated in vitro activity and preclinical efficacy against multi-drug resistant Gram-negative and Gram-positive strains of bacteria known to cause complicated urinary tract, skin and lung infections, as well as sepsis.
Financial terms:
Latest news:
Is general: Yes
